Is it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist?

Successful Treatment of Generalized Pustular Psoriasis With the Interleukin-1-Receptor Antagonist Anakinra: Lack of Correlation With IL1RN Mutations

(2013) Manuelle Viguier   ANNALS OF INTERNAL MEDICINE

Successful therapy with anakinra in a patient with generalized pustular psoriasis carryingIL36RNmutations

(2013) U. Hüffmeier et al.   BRITISH JOURNAL OF DERMATOLOGY

First Clinical Description of an Infant With Interleukin-36-Receptor Antagonist Deficiency Successfully Treated With Anakinra

(2013) L. Rossi-Semerano et al.   PEDIATRICS

Efficacy and Safety of Tumor Necrosis Factor Inhibitors in Acute Generalized Pustular Psoriasis

(2012) Manuelle Viguier   ARCHIVES OF DERMATOLOGY

IL-36 in psoriasis

(2012) JE Towne et al.   CURRENT OPINION IN PHARMACOLOGY

Psoriasiform dermatitis is driven by IL-36–mediated DC-keratinocyte crosstalk

(2012) Luigi Tortola et al.   JOURNAL OF CLINICAL INVESTIGATION

Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis

(2011) Alexandros Onoufriadis et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis

(2011) Slaheddine Marrakchi et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist

(2009) Ivona Aksentijevich et al.   NEW ENGLAND JOURNAL OF MEDICINE